Cargando…
Personalized treatment of hepatitis B
There are seven approved drugs for treatment of hepatitis B. Professional guidelines provide a framework for managing patients but these guidelines should be interpreted in the context of the individual patient's clinical and social circumstances. Personalized management of hepatitis B can be a...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379190/ https://www.ncbi.nlm.nih.gov/pubmed/25834795 http://dx.doi.org/10.3350/cmh.2015.21.1.1 |
_version_ | 1782364161119879168 |
---|---|
author | Lok, Anna S. |
author_facet | Lok, Anna S. |
author_sort | Lok, Anna S. |
collection | PubMed |
description | There are seven approved drugs for treatment of hepatitis B. Professional guidelines provide a framework for managing patients but these guidelines should be interpreted in the context of the individual patient's clinical and social circumstances. Personalized management of hepatitis B can be applied based on prediction of the individual patient's risk of cirrhosis and hepatocellular carcinoma to guide the frequency and intensity of monitoring and urgency of treatment. It can also be applied to decisions regarding when to start treatment, which drug to use, and when to stop based on the individual patient's disease characteristics, preference, comorbidities and other mitigating circumstances. |
format | Online Article Text |
id | pubmed-4379190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-43791902015-04-01 Personalized treatment of hepatitis B Lok, Anna S. Clin Mol Hepatol Review There are seven approved drugs for treatment of hepatitis B. Professional guidelines provide a framework for managing patients but these guidelines should be interpreted in the context of the individual patient's clinical and social circumstances. Personalized management of hepatitis B can be applied based on prediction of the individual patient's risk of cirrhosis and hepatocellular carcinoma to guide the frequency and intensity of monitoring and urgency of treatment. It can also be applied to decisions regarding when to start treatment, which drug to use, and when to stop based on the individual patient's disease characteristics, preference, comorbidities and other mitigating circumstances. The Korean Association for the Study of the Liver 2015-03 2015-03-25 /pmc/articles/PMC4379190/ /pubmed/25834795 http://dx.doi.org/10.3350/cmh.2015.21.1.1 Text en Copyright © 2015 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Lok, Anna S. Personalized treatment of hepatitis B |
title | Personalized treatment of hepatitis B |
title_full | Personalized treatment of hepatitis B |
title_fullStr | Personalized treatment of hepatitis B |
title_full_unstemmed | Personalized treatment of hepatitis B |
title_short | Personalized treatment of hepatitis B |
title_sort | personalized treatment of hepatitis b |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379190/ https://www.ncbi.nlm.nih.gov/pubmed/25834795 http://dx.doi.org/10.3350/cmh.2015.21.1.1 |
work_keys_str_mv | AT lokannas personalizedtreatmentofhepatitisb |